Literature DB >> 30056575

Tyrosine Hydroxylase Inhibition in Substantia Nigra Decreases Movement Frequency.

Michael F Salvatore1, Tamara R McInnis2, Mark A Cantu2, Deana M Apple3, Brandon S Pruett4,5.   

Abstract

Reduced movement frequency or physical activity (bradykinesia) occurs with high prevalence in the elderly. However, loss of striatal tyrosine hydroxylase (TH) in aging humans, non-human primates, or rodents does not reach the ~ 80% loss threshold associated with bradykinesia onset in Parkinson's disease. Moderate striatal dopamine (DA) loss, either following TH inhibition or decreased TH expression, may not affect movement frequency. In contrast, moderate DA or TH loss in the substantia nigra (SN), as occurs in aging, is of similar magnitude (~ 40%) to nigral TH loss at bradykinesia onset in Parkinson's disease. In aged rats, increased TH expression and DA in SN alone increases movement frequency, suggesting aging-related TH and DA loss in the SN contributes to aging-related bradykinesia or decreased physical activity. To test this hypothesis, the SN was targeted with bilateral guide cannula in young (6 months old) rats, in a within-subjects design, to evaluate the impact of nigral TH inhibition on movement frequency and speed. The TH inhibitor, α-methyl-p-tyrosine (AMPT) reduced nigral DA (~ 40%) 45-150 min following infusion, without affecting DA in striatum, nucleus accumbens, or adjacent ventral tegmental area. Locomotor activity in the open-field was recorded up to 3 h following nigral saline or AMPT infusion in each test subject. During the period of nigra-specific DA reduction, movement frequency, but not movement speed, was significantly decreased. These results indicate that DA or TH loss in the SN, as observed in aging, contributes as a central mechanism of reduced movement frequency.

Entities:  

Keywords:  Aging; Locomotor; Movement; Parkinson’s; Substantia nigra; Tyrosine hydroxylase

Mesh:

Substances:

Year:  2018        PMID: 30056575      PMCID: PMC6349536          DOI: 10.1007/s12035-018-1256-9

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  78 in total

1.  Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson's disease.

Authors:  Timothy J Collier; Caryl E Sortwell; John D Elsworth; Jane R Taylor; Robert H Roth; John R Sladek; D Eugene Redmond
Journal:  J Comp Neurol       Date:  2002-01-21       Impact factor: 3.215

2.  Effect of bilateral 6-hydroxydopamine lesions of the medial forebrain bundle on reaction time.

Authors:  A D Smith; M Amalric; G F Koob; M J Zigmond
Journal:  Neuropsychopharmacology       Date:  2002-06       Impact factor: 7.853

Review 3.  Age-related decline in physical activity: generalization to nonhumans.

Authors:  D K Ingram
Journal:  Med Sci Sports Exerc       Date:  2000-09       Impact factor: 5.411

4.  Release of dopamine from dendrites in rat substantia nigra.

Authors:  L B Geffen; T M Jessell; A C Cuello; L L Iversen
Journal:  Nature       Date:  1976-03-18       Impact factor: 49.962

5.  Substantia nigra pars reticulata is a highly potent site of action for the behavioral effects of the D1 antagonist SCH 23390 in the rat.

Authors:  J T Trevitt; B B Carlson; K Nowend; J D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2001-06       Impact factor: 4.530

6.  Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys.

Authors:  Greg A Gerhardt; Wayne A Cass; Ai Yi; Zhiming Zhang; Don M Gash
Journal:  J Neurochem       Date:  2002-01       Impact factor: 5.372

7.  Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system.

Authors:  D Kirik; C Rosenblad; A Bjorklund; R J Mandel
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

8.  Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Authors:  E Bezard; S Dovero; C Prunier; P Ravenscroft; S Chalon; D Guilloteau; A R Crossman; B Bioulac; J M Brotchie; C E Gross
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

9.  Somatodendritic dopamine release in rat substantia nigra influences motor performance on the accelerating rod.

Authors:  Filip Bergquist; Haydeh Niazi Shahabi; Hans Nissbrandt
Journal:  Brain Res       Date:  2003-05-23       Impact factor: 3.252

10.  Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum.

Authors:  John W Haycock; Laurence Becker; Lee Ang; Yoshiaki Furukawa; Oleh Hornykiewicz; Stephen J Kish
Journal:  J Neurochem       Date:  2003-11       Impact factor: 5.372

View more
  8 in total

1.  Modulation of nigral dopamine signaling mitigates parkinsonian signs of aging: evidence from intervention with calorie restriction or inhibition of dopamine uptake.

Authors:  Michael F Salvatore; Ella A Kasanga; D Parker Kelley; Katy E Venable; Tamara R McInnis; Mark A Cantu; Jennifer Terrebonne; Kathryn Lanza; Samantha M Meadows; Ashley Centner; Christopher Bishop; Donald K Ingram
Journal:  Geroscience       Date:  2022-05-30       Impact factor: 7.713

2.  Nanostructure lipid carriers enhance alpha-mangostin neuroprotective efficacy in mice with rotenone-induced neurodegeneration.

Authors:  Romgase Sakamula; Teerapong Yata; Wachiryah Thong-Asa
Journal:  Metab Brain Dis       Date:  2022-03-30       Impact factor: 3.655

3.  Psychological Stress Phenocopies Brain Mitochondrial Dysfunction and Motor Deficits as Observed in a Parkinsonian Rat Model.

Authors:  Mariana Grigoruţă; Alejandro Martínez-Martínez; Raul Y Dagda; Ruben K Dagda
Journal:  Mol Neurobiol       Date:  2019-12-14       Impact factor: 5.590

Review 4.  Alterations of Cytochrome P450s and UDP-Glucuronosyltransferases in Brain Under Diseases and Their Clinical Significances.

Authors:  Yun Sheng; Hanyu Yang; Tong Wu; Liang Zhu; Li Liu; Xiaodong Liu
Journal:  Front Pharmacol       Date:  2021-04-21       Impact factor: 5.810

5.  Cardiovascular Metrics Associated With Prevention of Aging-Related Parkinsonian Signs Following Exercise Intervention in Sedentary Older Rats.

Authors:  Ella A Kasanga; Joel Little; Tamara R McInnis; Nicoleta Bugnariu; J Thomas Cunningham; Michael F Salvatore
Journal:  Front Aging Neurosci       Date:  2021-12-15       Impact factor: 5.750

6.  Circulatory 25(OH)D and 1,25(OH)2D as differential biomarkers between multiple system atrophy and Parkinson's disease patients.

Authors:  Hiromu Ogura; Izzettin Hatip-Al-Khatib; Midori Suenaga; Funda Bolukbasi Hatip; Takayasu Mishima; Shinsuke Fujioka; Shinji Ouma; Yoichi Matsunaga; Yoshio Tsuboi
Journal:  eNeurologicalSci       Date:  2021-09-23

7.  Cannabinoid Receptor 1 Is Required for Neurodevelopment of Striosome-Dendron Bouquets.

Authors:  Jill R Crittenden; Tomoko Yoshida; Samitha Venu; Ara Mahar; Ann M Graybiel
Journal:  eNeuro       Date:  2022-04-11

8.  Blueberry juice augments exercise-induced neuroprotection in a Parkinson's disease model through modulation of GDNF levels.

Authors:  Sandra L Castro; Victor Tapias; Ronald Gathagan; Alexandra Emes; Taylor E Brandon; Amanda D Smith
Journal:  IBRO Neurosci Rep       Date:  2022-03-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.